Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ARGXBullishAnalyst Target Updateanalyst

Medium materiality6/10

Argenx price target raised to $1,025 from $945 at RBC Capital

Jul 23, 2026, 5:12 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Analyst target changes matter most when the new target creates a material gap versus current price or confirms a recent catalyst.

AI summary

What happened, with direct paths to the underlying reporting

RBC Capital raises Argenx (ARGX) price target to $1,025 from $945; current price around $924.60.

RBC raises ARGX target to $1,025; current price ~ $924.60

Key facts

01
Target: $1,025
02
Posted price: $924.6
03
Analyst firm: RBC Capital

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Argenx price target raised to $1,025 from $945 at RBC Capital

Key facts

argenx Announces Positive Phase 3 ALKIVIA Topline for VYVGART Hytrulo in Autoimmune Myositis

Argenx to acquire Forte Biosciences for $2.2B, expanding CD122 pipeline

Argenx Reframes Phase 3 Myositis Readout; IMNM Upside Supports Bullish View

ARGX Gains on FDA Expansion of VYVGART Usage in Myasthenia Gravis